Inhibrx is progressing its cancer treatments ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets. Ozekibart showed a 52% risk reduction in chondrosarcoma progression and strong responses in colorectal and Ewing sarcoma, leading to previous stock gains. INBRX-106 combined with Keytruda demonstrated promising results in head and neck cancer, especially in HPV+ patients. The FDA will decide on ozekibart's Biologics License Application by April 2027, with Inhibrx expanding Phase 2 trials for INBRX-106 aiming for accelerated approval in a $4 billion HPV+ head and neck cancer market and broader immunogenic tumor opportunities worth over $50 billion.
Chewy reported quarterly earnings of $0.36 per share, doubling analyst estimates of $0.18, with net income rising to $80.5 million from $62 million a year ago. Quarterly revenue reached $3.33 billion, slightly above expectations, marking a 7.3% incre...
AeroVironment, a leading drone maker, is set to report its Q3 earnings on September 9, 2026, with analysts expecting EPS between $0.22 and $0.25 and revenue near $452-$456 million. The company recently secured major contracts worth over $865 million ...
Bernstein has reduced the price target for Newmont Corporation to $144, reflecting challenges including a 13% drop in gold production and rising costs expected to reach $1,680 per ounce in 2026. Despite these issues, Newmont's stock gained 34.5% in A...
Barrick Mining maintains an 'Outperform' rating from Bernstein despite a lowered price target of $56.50, down from $61.00. The company reported an 11% increase in gold production in Q2 to 796,000 ounces, with further growth expected in the coming qua...
Paychex, a leading HR and payroll services provider, has seen its stock rise 30% over six months due to strong financial performance and strategic growth initiatives. The company leverages its AI-powered WISE platform to improve efficiency and profit...
